ROS1 R2033N

CI-VAR-00003757Explore in graph →CIViC 2857

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ROS1 R2033N	Cabozantinib	Predictive	C	Supports Sensitivity Response	3	rejected	EID7690 A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months achieved tumor response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 R2033N mut… (full text at CIViC) PMID 26673800 · Drilon et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.